Cargando…

INSTI-Based Triple Regimens in Treatment-Naïve HIV-Infected Patients Are Associated With HIV-RNA Viral Load Suppression at Ultralow Levels

BACKGROUND: During antiretroviral therapy (ART), HIV-1-infected patients may present with ultralow (UL) HIV-RNA viral loads (VLs) below quantification levels of current assays. Reasons for UL-VL detection and its relation to virological rebound (VR) are unclear. METHODS: HIV-1-infected, ART-naïve pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lambert-Niclot, Sidonie, Boyd, Anders, Fofana, Djeneba, Valin, Nadia, Wirden, Marc, Meynard, Jean-Luc, Palich, Romain, Agher, Rachid, Valantin, Marc-Antoine, Calvez, Vincent, Katlama, Christine, Girard, Pierre-Marie, Marcelin, Anne-Geneviève, Morand-Joubert, Laurence
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524833/ https://www.ncbi.nlm.nih.gov/pubmed/31123690 http://dx.doi.org/10.1093/ofid/ofz177

Ejemplares similares

Similar Evolution of Cellular HIV-1 DNA Level in Darunavir/Ritonavir Monotherapy versus Triple Therapy in MONOI –ANRS136 Trial over 96 Weeks
por: Lambert-Niclot, Sidonie, et al.
Publicado: (2012)

High SARS-CoV-2 seroprevalence in HIV patients originating from sub-Saharan Africa in the Ile-de-France area: Seroprevalence of SARS-CoV-2 in HIV patients
por: ABDI, Basma, et al.
Publicado: (2022)

Prevalence of HIV-1 Natural Polymorphisms and Integrase-Resistance-Associated Mutations in African Children
por: Fofana, Djeneba B., et al.
Publicado: (2023)

The Role of Radiotherapy in Treating Kaposi’s Sarcoma in HIV Infected Patients
por: Quéro, Laurent, et al.
Publicado: (2022)

Week 48 efficacy of 900/100 mg daily of darunavir/ritonavir in treatment-experienced HIV-1 patients with virological success: DARDAR study
por: Schneider, L, et al.
Publicado: (2010)

Caution in interpretation of SARS-CoV-2 quantification based on RT-PCR cycle threshold value
por: Schnuriger, Aurélie, et al.
Publicado: (2021)

Intermittent Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment Maintains High Level of Viral Suppression in Virally Suppressed People Living with HIV
por: Sellem, Baptiste, et al.
Publicado: (2023)

HIV Replication Is Not Controlled by CD8(+) T Cells during the Acute Phase of the Infection in Humanized Mice
por: Petit, Nicolas Y., et al.
Publicado: (2015)

The 501Y.V2 SARS-CoV-2 variant has an intermediate viral load between the 501Y.V1 and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients
por: Teyssou, Elisa, et al.
Publicado: (2021)

Prevalence of resistance and HIV-1 protease mutation patterns after failures with fosamprenavir-containing regimens
por: Marcelin, AG, et al.
Publicado: (2010)

Less frequent follow-up in routine care than in trials does not impact resistance selection in patients failing DRV/r or ATV/r first line treatment
por: Marcelin, Anne-Genevieve, et al.
Publicado: (2014)

Description of the L76V Resistance Protease Mutation in HIV-1 B and “Non-B” Subtypes
por: Charpentier, Charlotte, et al.
Publicado: (2013)

Performance and usability evaluation of the INSTI HIV self-test in Kenya for qualitative detection of antibodies to HIV
por: Bwana, Priska, et al.
Publicado: (2018)

Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV
por: Dow, Dorothy E., et al.
Publicado: (2014)

SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization Test
por: Marot, Stephane, et al.
Publicado: (2022)

Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV
por: Devred, Inès, et al.
Publicado: (2023)

Long COVID-19 symptoms: Clinical characteristics and recovery rate among non-severe outpatients over a six-month follow-up
por: Seang, S., et al.
Publicado: (2022)

A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection
por: Zhao, Alexa Vyain, et al.
Publicado: (2022)

New HIV-1 circulating recombinant form 94: from phylogenetic detection of a large transmission cluster to prevention in the age of geosocial-networking apps in France, 2013 to 2017
por: Wirden, Marc, et al.
Publicado: (2019)

Olfactory and gustatory dysfunctions in COVID-19 outpatients: A prospective cohort study
por: Cousyn, L., et al.
Publicado: (2021)

Efficacy of once daily darunavir/ritonavir 800/100 mg in PI/r-experienced HIV-1 infected patients with suppressed HIV-1 replication: the RADAR study
por: Ghosn, J, et al.
Publicado: (2010)

Darunavir resistance spectrum in darunavir-na#239;ve patients harboring virological failure to antiretroviral therapy
por: Marcelin, AG, et al.
Publicado: (2010)

2492. Differences between Individuals Currently Taking Integrase Inhibitor (INSTI)-based Therapy and Those Not Taking INSTIs in the Era of INSTIs as Recommended First-line Therapy
por: Monroe, Anne K, et al.
Publicado: (2019)

Detection of Early Sero-Conversion HIV Infection Using the INSTI(TM) HIV-1 Antibody Point-of-Care Test
por: Cook, Darrel, et al.
Publicado: (2010)

1499. Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV
por: McLaughlin, Taryn, et al.
Publicado: (2023)

Seroprevalence and risk factors for HIV, HCV, HBV and syphilis among blood donors in Mali
por: Jary, Aude, et al.
Publicado: (2019)

Safety and efficacy of pharmacotherapy containing INSTIs and chemotherapy drugs in people living with HIV and concomitant colorectal cancer
por: Yang, Jing, et al.
Publicado: (2022)

Prevalence of resistance to integrase strand-transfer inhibitors (INSTIs) among untreated HIV-1 infected patients in Morocco
por: Alaoui, Najwa, et al.
Publicado: (2018)

Genetic Features of HIV-1 Integrase Sub-Subtype A6 Predominant in Russia and Predicted Susceptibility to INSTIs
por: Kirichenko, Alina, et al.
Publicado: (2020)

A push for 90-90-90: Initial treatment with INSTI-based regimens against HIV-1 infection
por: Rusconi, Stefano, et al.
Publicado: (2019)

Durability of Integrase STrand Inhibitor (InSTI)-based regimen in geriatric people living with HIV in the GEPPO cohort
por: Focà, Emanuele, et al.
Publicado: (2021)

INSTIs and NNRTIs Potently Inhibit HIV-1 Polypurine Tract Mutants in a Single Round Infection Assay
por: Smith, Steven J., et al.
Publicado: (2021)

Selected CNS Outcomes Among INSTI Antiretrovirals
por: Wohl, David, et al.
Publicado: (2017)

The Emergence of Resistance Under Firstline INSTI Regimens
por: Xie, Zhiman, et al.
Publicado: (2022)

Invalid Results in the GetaKit Study in Ottawa: A Real-World Observation of the INSTI® HIV Self-test Among Persons At Risk for HIV
por: O'Byrne, Patrick, et al.
Publicado: (2022)

GRL-142 binds to and impairs HIV-1 integrase nuclear localization signal and potently suppresses highly INSTI-resistant HIV-1 variants
por: Aoki, Manabu, et al.
Publicado: (2023)

Kaposi’s Sarcoma in Virally Suppressed People Living with HIV: An Emerging Condition
por: Palich, Romain, et al.
Publicado: (2021)

1043. The impact of integrase strand transfer inhibitors (InSTIs) on weight gain among adults with HIV in clinical care
por: Thatipelli, Sneha, et al.
Publicado: (2020)

1566. Determinants associated with weight gain among persons with HIV who switch to integrase strand transfer inhibitors (INSTI)
por: Cutshaw, Melissa Klein, et al.
Publicado: (2023)

Immune Reconstitution Inflammatory Syndrome Associated Kaposi Sarcoma
por: Poizot-Martin, Isabelle, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qigpt7usc2812a7aaa96qcas78